The TDHS decided again this week not to give us any vaccine. Here is where it went. https://dshs.texas.gov/news/updates/COVIDVaccineAllocation-Week15.pdf
Interestingly, this doesn’t include large pharmacy chains who must be getting it directly for the government. As you can see the vaccine is mainly going to University Health, San Antonio Metropolitan Health and Wellmed.
Here are some encouraging vaccine facts.
Another encouraging development is the study on the efficacy of Astra Zeneca’s vaccine which has been studied in the US. Here is a summary from Physician’s First Watch.
By Kelly Young
AstraZeneca’s two-dose adenovirus-vectored vaccine (AZD1222) had 79% efficacy in preventing symptomatic COVID-19 among adults in the U.S., Peru, and Chile, according to interim phase 3 trial results. The company expects to request emergency use authorization in the U.S. in the coming weeks.
Researchers randomized over 32,000 adults at increased risk for COVID-19 to receive two doses of the vaccine or placebo, 4 weeks apart. Of these, 141 people developed symptomatic COVID-19. In addition to preventing symptomatic illness, the vaccine had 100% efficacy for preventing severe or critical disease and hospitalization.
For adults 65 and older, the efficacy against symptomatic COVID-19 was 80%.
Of the 22,000 people who received at least one dose of the vaccine, none developed cerebral venous sinus thrombosis (CVST), higher rates of which have been observed in vaccine recipients in Europe. There was also no increased risk for thrombosis in general.
As mentioned above there was no evidence of increased risk of blood clots. In a report published last week, the vaccine was not effective against the South Africa variant.